Showing results (121-130 of 151) with videos related to
Sort By:
Pageof 16
BMJ Open|October 22, 2024
Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trialDaniel Vincent O'Hara, Abhinav Bassi, Arlen Wilcox, et al.Kidney International Reports|September 12, 2022
Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of UtilityGlen James, Juan Jose Garcia Sanchez, Juan Jesus Carrero, et al.JMIR Research Protocols|April 15, 2020
EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort StudyCeline Foote, Carinna Hockham, Louisa Sukkar, et al.Journal of the American Heart Association|June 22, 2023
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE TrialsRobert A Fletcher, Clare Arnott, Patrick Rockenschaub, et al.BMJ (Clinical Research Ed.)|November 17, 2022
Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trialMeg J Jardine, Sradha S Kotwal, Abhinav Bassi, et al.Trials|August 20, 2015
Standardised outcomes in nephrology - Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysisAllison Tong, Braden Manns, Brenda Hemmelgarn, et al.Journal of Clinical & Translational Endocrinology|December 9, 2020
Prevalence, incidence and risk factors of diabetes in Australian adults aged ≥45 years: A cohort study using linked routinely-collected dataHongmei Zhang, Kris Rogers, Louisa Sukkar, et al.European Heart Journal|August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trialBrendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.American Heart Journal|December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trialAshish Sarraju, JingWei Li, Christopher P Cannon, et al.Kidney International|December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practiceMegumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.Pageof 16